Kairos Pharma Ltd (KAPA)

May 6, 2025, 8:00 AM EDT - 8 days ago

Kairos Pharma, Ltd. Announces Participation in the D.

Apr 28, 2025, 8:00 AM EDT - 16 days ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 20 days ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 17, 2025, 8:00 AM EDT - 27 days ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Mar 31, 2025, 7:00 AM EDT - 6 weeks ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 27, 2025, 4:05 PM EDT - 6 weeks ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Mar 20, 2025, 7:30 AM EDT - 7 weeks ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Feb 26, 2025, 7:00 AM EST - 2 months ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Feb 18, 2025, 8:30 AM EST - 3 months ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Feb 11, 2025, 8:30 AM EST - 3 months ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 6, 2025, 8:30 AM EST - 3 months ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Jan 28, 2025, 8:15 AM EST - 3 months ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 21, 2025, 8:30 AM EST - 4 months ago

Kairos Pharma Provides Business Update and Outlook into 2025

Jan 7, 2025, 8:15 AM EST - 4 months ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Dec 26, 2024, 7:51 AM EST - 4 months ago

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Dec 16, 2024, 12:15 PM EST - 5 months ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 3, 2024, 8:30 AM EST - 5 months ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Nov 26, 2024, 8:30 AM EST - 6 months ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Oct 22, 2024, 9:00 AM EDT - 7 months ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 9, 2024, 4:30 PM EDT - 7 months ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 24, 2024, 4:20 PM EDT - 8 months ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 21, 2024, 2:00 AM EDT - 8 months ago

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

BIOA BKV FBGL GLE GRDN LGCY PRB

Sep 17, 2024, 4:29 PM EDT - 8 months ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 8 months ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Feb 14, 2024, 6:16 PM EST - 1 year ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Oct 3, 2023, 3:33 PM EDT - 1 year ago

Kairos Pharma Files For U.S. IPO